Guggenheim Capital LLC Cara Therapeutics, Inc. Transaction History

Guggenheim Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.24 - $12.56 $111,141 - $169,409	-13,488 Reduced 56.0%	10,598 $99,000
Q2 2022 Aug 15, 2022	BUY	$7.45 - $13.84 $90,048 - $167,284	12,087 Added 100.73%	24,086 $219,000
Q1 2022 May 16, 2022	SELL	$9.94 - $12.65 $3,230 - $4,111	-325 Reduced 2.64%	11,999 $145,000
Q4 2021 Feb 14, 2022	BUY	$11.99 - $18.14 $147,764 - $223,557	12,324 New	12,324 $150,000
Q4 2017 Feb 14, 2018	SELL	$11.86 - $14.08 $1.29 Million - $1.53 Million	-108,958 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$12.6 - $16.34 $1.37 Million - $1.78 Million	108,958	108,958 $1.49 Million

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.